• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Abbott’s New Libre Assist AI Tool Might Change The Case For Investing In Abbott Laboratories (ABT)

    Simply Wall St·01/06/2026 16:22:42
    语音播报
    • In early January 2026, Abbott Laboratories launched Libre Assist, an AI-powered feature within its Libre diabetes app that uses food photos or text descriptions plus continuous glucose data to help U.S. users predict and understand the impact of meals on their glucose levels before and after eating.
    • This move highlights Abbott’s effort to turn its FreeStyle Libre franchise into a more integrated, software-centered diabetes management platform rather than a standalone hardware device.
    • We’ll now examine how Abbott’s push into AI-driven, software-based diabetes tools with Libre Assist could reshape its broader investment narrative.

    The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 25 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

    Abbott Laboratories Investment Narrative Recap

    To own Abbott, you need to believe its diversified healthcare model and diabetes technology can offset pressure in diagnostics and pricing. Libre Assist reinforces the central role of FreeStyle Libre, but its financial impact will likely be modest near term, with the upcoming Q4 2025 earnings call remaining the key checkpoint. The biggest near term risk still sits in pricing and competitive pressure across diagnostics and continuous glucose monitoring rather than any single software feature.

    Among recent announcements, the Q4 2025 earnings release scheduled for January 22, 2026, is the most relevant in light of Libre Assist. That call should clarify how Abbott positions AI driven software within its broader Libre ecosystem and how management frames this against ongoing headwinds in COVID related testing, China volume based procurement and pressure on margins from tariffs and foreign exchange.

    However, investors should also weigh how intensifying CGM competition and potential US competitive bidding could affect Abbott’s pricing power and long term profitability...

    Read the full narrative on Abbott Laboratories (it's free!)

    Abbott Laboratories' narrative projects $53.3 billion revenue and $9.4 billion earnings by 2028. This requires 7.3% yearly revenue growth and a $4.5 billion earnings decrease from $13.9 billion.

    Uncover how Abbott Laboratories' forecasts yield a $144.43 fair value, a 14% upside to its current price.

    Exploring Other Perspectives

    ABT 1-Year Stock Price Chart
    ABT 1-Year Stock Price Chart

    Ten fair value estimates from the Simply Wall St Community span roughly US$73 to US$144 per share, reflecting very different views on Abbott. You can set those side by side with the risk that competitive bidding and CGM rivalry may pressure Libre pricing and, in turn, the broader earnings profile.

    Explore 10 other fair value estimates on Abbott Laboratories - why the stock might be worth as much as 14% more than the current price!

    Build Your Own Abbott Laboratories Narrative

    Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

    Interested In Other Possibilities?

    Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.